These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34195300)

  • 1. Maternal Immune System and State of Inflammation Dictate the Fate and Severity of Disease in Preeclampsia.
    Zhao X; Chen S; Zhao C; Xia F
    J Immunol Res; 2021; 2021():9947884. PubMed ID: 34195300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble fms-like tyrosine kinase-1 and soluble endoglin in HIV-associated preeclampsia.
    Govender N; Naicker T; Rajakumar A; Moodley J
    Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):100-5. PubMed ID: 23806447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammatory cytokines, placental pathology, and neurological outcomes in infants born to preterm preeclamptic mothers.
    Sotiros A; Thornhill D; Post MD; Winn VD; Armstrong J
    PLoS One; 2021; 16(11):e0260094. PubMed ID: 34780565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An analysis on the roles of angiogenesis-related factors including serum vitamin D, soluble endoglin (sEng), soluble fms-like tyrosine kinase 1 (sFlt1), and vascular endothelial growth factor (VEGF) in the diagnosis and severity of late-onset preeclampsia.
    Cim N; Kurdoglu M; Ege S; Yoruk I; Yaman G; Yildizhan R
    J Matern Fetal Neonatal Med; 2017 Jul; 30(13):1602-1607. PubMed ID: 27658884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of female fetal sex on preeclampsia and the maternal immune milieu.
    Taylor BD; Ness RB; Klebanoff MA; Tang G; Roberts JM; Hougaard DM; Skogstrand K; Haggerty CL
    Pregnancy Hypertens; 2018 Apr; 12():53-57. PubMed ID: 29674199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activating Transcription Factor 3 Is Reduced in Preeclamptic Placentas and Negatively Regulates sFlt-1 (Soluble fms-Like Tyrosine Kinase 1), Soluble Endoglin, and Proinflammatory Cytokines in Placenta.
    Kaitu'u-Lino TJ; Brownfoot FC; Hastie R; Chand A; Cannon P; Deo M; Tuohey L; Whitehead C; Hannan NJ; Tong S
    Hypertension; 2017 Nov; 70(5):1014-1024. PubMed ID: 28947613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.
    Brownfoot FC; Hastie R; Hannan NJ; Cannon P; Tuohey L; Parry LJ; Senadheera S; Illanes SE; Kaitu'u-Lino TJ; Tong S
    Am J Obstet Gynecol; 2016 Mar; 214(3):356.e1-356.e15. PubMed ID: 26721779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia?
    Bdolah Y; Lam C; Rajakumar A; Shivalingappa V; Mutter W; Sachs BP; Lim KH; Bdolah-Abram T; Epstein FH; Karumanchi SA
    Am J Obstet Gynecol; 2008 Apr; 198(4):428.e1-6. PubMed ID: 18191808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased plasma soluble fms-like tyrosine kinase 1 and endoglin levels in pregnancies complicated with preeclampsia.
    Chedraui P; Lockwood CJ; Schatz F; Buchwalder LF; Schwager G; Guerrero C; Escobar GS; Hidalgo L
    J Matern Fetal Neonatal Med; 2009 Jul; 22(7):565-70. PubMed ID: 19350449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.
    Levine RJ; Lam C; Qian C; Yu KF; Maynard SE; Sachs BP; Sibai BM; Epstein FH; Romero R; Thadhani R; Karumanchi SA;
    N Engl J Med; 2006 Sep; 355(10):992-1005. PubMed ID: 16957146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First trimester serum angiogenic and anti-angiogenic factors in women with chronic hypertension for the prediction of preeclampsia.
    Nzelu D; Biris D; Karampitsakos T; Nicolaides KK; Kametas NA
    Am J Obstet Gynecol; 2020 Apr; 222(4):374.e1-374.e9. PubMed ID: 31705883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies.
    Holme AM; Roland MC; Henriksen T; Michelsen TM
    Am J Obstet Gynecol; 2016 Dec; 215(6):782.e1-782.e9. PubMed ID: 27503620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies.
    Powers RW; Jeyabalan A; Clifton RG; Van Dorsten P; Hauth JC; Klebanoff MA; Lindheimer MD; Sibai B; Landon M; Miodovnik M;
    PLoS One; 2010 Oct; 5(10):e13263. PubMed ID: 20948996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased expression of NLRP3 inflammasome in placentas from pregnant women with severe preeclampsia.
    C Weel I; Romão-Veiga M; Matias ML; Fioratti EG; Peraçoli JC; Borges VT; Araujo JP; Peraçoli MT
    J Reprod Immunol; 2017 Sep; 123():40-47. PubMed ID: 28915449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiogenic markers and their longitudinal change for predicting adverse outcomes in pregnant women with chronic hypertension.
    Binder J; Kalafat E; Palmrich P; Pateisky P; Khalil A
    Am J Obstet Gynecol; 2021 Sep; 225(3):305.e1-305.e14. PubMed ID: 33812812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of increased cord blood soluble endoglin with the development of bronchopulmonary dysplasia in preterm infants with maternal preeclampsia.
    Kim DH; Shin SH; Kim EK; Kim HS
    Pregnancy Hypertens; 2018 Jul; 13():148-153. PubMed ID: 30177044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma concentrations of soluble endoglin in the maternal circulation are associated with maternal vascular malperfusion lesions in the placenta of women with preeclampsia.
    Schmella MJ; Assibey-Mensah V; Parks WT; Roberts JM; Jeyabalan A; Hubel CA; Catov JM
    Placenta; 2019 Mar; 78():29-35. PubMed ID: 30955708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-4 deficiency induces mild preeclampsia in mice.
    Chatterjee P; Kopriva SE; Chiasson VL; Young KJ; Tobin RP; Newell-Rogers K; Mitchell BM
    J Hypertens; 2013 Jul; 31(7):1414-23; discussion 1423. PubMed ID: 23552130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological mechanisms in preeclampsia: A narrative review.
    Javandoust Gharehbagh F; Soltani-Zangbar MS; Yousefzadeh Y
    J Reprod Immunol; 2024 Aug; 164():104282. PubMed ID: 38901108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate.
    Romero R; Nien JK; Espinoza J; Todem D; Fu W; Chung H; Kusanovic JP; Gotsch F; Erez O; Mazaki-Tovi S; Gomez R; Edwin S; Chaiworapongsa T; Levine RJ; Karumanchi SA
    J Matern Fetal Neonatal Med; 2008 Jan; 21(1):9-23. PubMed ID: 18175241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.